Dutch biotech firm, VectorY, has raised $138m to advance its antibody technology in the treatment of neurodegenerative diseases, particularly ALS. By targeting the misfolded protein TDP-43 with antibodies, VectorY’s drug therapy could potentially tackle an aggressive form of ALS that has previously proved difficult to treat. The funding will be used to push the lead programme, VTX-002, into clinical trials which are hoped to begin in early 2025.
UK retailer Co-Op says systems now running normally after cyber incident – 1470 & 100.3 WMBD
UK retailer Co-Op announced that its systems are now operating normally following a recent cyber incident. The company has addressed the issues caused by the
